+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Post Traumatic Stress Disorder Drug"

From
From
Post-traumatic Stress Disorder (PTSD) - Pipeline Insight, 2024 - Product Thumbnail Image

Post-traumatic Stress Disorder (PTSD) - Pipeline Insight, 2024

  • Clinical Trials
  • February 2024
  • 80 Pages
  • Global
From
Global Psychedelic Drugs Market Analysis & Forecast to 2024-2034 - Product Thumbnail Image

Global Psychedelic Drugs Market Analysis & Forecast to 2024-2034

  • Report
  • January 2024
  • 200 Pages
  • Global
From
From
From
From
From
From
From
From
From
Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2020 - Product Thumbnail Image

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2020

  • Drug Pipelines
  • July 2020
  • 195 Pages
  • Global
From
  • 18 Results (Page 1 of 1)
Loading Indicator

The Post Traumatic Stress Disorder (PTSD) Drug market is a subset of the Mental Disorders Drugs market. PTSD is a mental health condition that can develop after a person experiences a traumatic event. It is characterized by symptoms such as flashbacks, nightmares, and difficulty sleeping. Treatment for PTSD typically includes psychotherapy and medications. Common medications used to treat PTSD include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and atypical antipsychotics. The PTSD Drug market is expected to grow due to increasing prevalence of PTSD, rising awareness about mental health, and increasing government initiatives to reduce the stigma associated with mental health disorders. Additionally, the development of novel drugs and the increasing use of digital therapeutics are expected to drive the market growth. Some companies in the PTSD Drug market include Eli Lilly, Pfizer, GlaxoSmithKline, Johnson & Johnson, Merck, and Novartis. Show Less Read more